Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.
Cingolani A, Cozzi-Lepri A, Ammassari A, Mussini C, Ursitti MA, Caramello P, Angarano G, Bonfanti P, De Luca A, Mura MS, Girardi E, Antinori A, Monforte AD; Icona Foundation Study group. Cingolani A, et al. Among authors: monforte ad. PLoS One. 2014 Feb 27;9(2):e89861. doi: 10.1371/journal.pone.0089861. eCollection 2014. PLoS One. 2014. PMID: 24587081 Free PMC article.
Evolution of the prevalence of hepatitis C virus infection and hepatitis C virus genotype distribution in human immunodeficiency virus-infected patients in Italy between 1997 and 2015.
Rossetti B, Bai F, Tavelli A, Galli M, Antinori A, Castelli F, Pellizzer G, Cozzi-Lepri A, Bonora S, Monforte AD, Puoti M, De Luca A; ICONA Foundation study group. Rossetti B, et al. Among authors: monforte ad. Clin Microbiol Infect. 2018 Apr;24(4):422-427. doi: 10.1016/j.cmi.2017.07.021. Epub 2017 Jul 29. Clin Microbiol Infect. 2018. PMID: 28765078 Free article.
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide or dual therapy-based regimens in HIV-infected individuals with viral load ≤50 copies/mL: does estimated glomerular filtration rate matter?
Vergori A, Gagliardini R, Gianotti N, Gori A, Lichtner M, Saracino A, De Vito A, Cascio A, Di Biagio A, Monforte AD, Antinori A, Cozzi-Lepri A; ICONA Foundation Study Network. Vergori A, et al. Among authors: monforte ad. Int J Antimicrob Agents. 2020 Dec;56(6):106154. doi: 10.1016/j.ijantimicag.2020.106154. Epub 2020 Sep 10. Int J Antimicrob Agents. 2020. PMID: 32919008
Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration.
Tusch E, Ryom L, Pelchen-Matthews A, Mocroft A, Elbirt D, Oprea C, Günthard HF, Staehelin C, Zangerle R, Suarez I, Vehreschild JJ, Wit F, Menozzi M, d'Arminio Monforte A, Spagnuolo V, Pradier C, Carlander C, Suanzes P, Wasmuth JC, Carr A, Petoumenos K, Borgans F, Bonnet F, De Wit S, El-Sadr W, Neesgaard B, Jaschinski N, Greenberg L, Hosein SR, Gallant J, Vannappagari V, Young L, Sabin C, Lundgren J, Peters L, Reekie J; D:A:D cohort study; RESPOND cohort study. Tusch E, et al. Clin Infect Dis. 2024 Apr 26:ciae228. doi: 10.1093/cid/ciae228. Online ahead of print. Clin Infect Dis. 2024. PMID: 38663013
Combined bictegravir, emtricitabine and tenofovir alafenamide for treating people with HIV: a plain language summary of the BICSTaR study up to 1 year.
Esser S, Inciarte A, Levy I, Monforte AD, Lambert JS, Welzen BV, Teruya K, Boffito M, Liu CE, Aydın OA, Thorpe D, Heinzkill M, Marongiu A, Cassidy T, Haubrich R, D'Amato L, Robineau O. Esser S, et al. Among authors: monforte ad. Future Microbiol. 2024 Sep 4:1-10. doi: 10.1080/17460913.2024.2391190. Online ahead of print. Future Microbiol. 2024. PMID: 39229785
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona).
Mazzotta V, Nozza S, Lanini S, Moschese D, Tavelli A, Rossotti R, Fusco FM, Biasioli L, Matusali G, Raccagni AR, Mileto D, Maci C, Lapadula G, Di Biagio A, Pipitò L, Tamburrini E, Monforte AD, Castagna A, Antinori A; mpox-Icona study group. Mazzotta V, et al. Among authors: monforte ad. EBioMedicine. 2024 Sep;107:105289. doi: 10.1016/j.ebiom.2024.105289. Epub 2024 Aug 22. EBioMedicine. 2024. PMID: 39178746 Free PMC article.
Integrase strand transfer inhibitor (INSTI) related changes in BMI and risk of diabetes: a prospective study from the RESPOND cohort consortium.
Rupasinghe D, Bansi-Matharu L, Law M, Zangerle R, Rauch A, Tarr PE, Greenberg L, Neesgaard B, Jaschinski N, De Wit S, Wit F, Monforte AD, Fontas E, Castagna A, Stecher M, Brandes V, Florence E, Begovac J, Mussini C, Sönnerborg A, Abutidze A, Groh A, Vannappagari V, Cohen C, Young L, Hosein S, Ryom L, Petoumenos K. Rupasinghe D, et al. Among authors: monforte ad. Clin Infect Dis. 2024 Aug 9:ciae406. doi: 10.1093/cid/ciae406. Online ahead of print. Clin Infect Dis. 2024. PMID: 39117341
Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir.
Bai F, Beringheli T, Vitaletti V, Santoro A, Molà F, Copes A, Gemignani N, Pettenuzzo S, Castoldi R, Varisco B, Nardo R, Lundgren LB, Ligresti R, Sala M, Albertini L, Augello M, Biasioli L, Bono V, Rovito R, Bini T, Passarella S, Orfeo NV, Monforte AD, Marchetti G. Bai F, et al. Among authors: monforte ad. Infect Dis Ther. 2024 Jul;13(7):1589-1605. doi: 10.1007/s40121-024-00994-3. Epub 2024 Jun 3. Infect Dis Ther. 2024. PMID: 38829439 Free PMC article.
265 results